[Antibody drug conjugates: Use and optimization in HER2-negative metastatic breast cancers (triple negative,...

Area of Science:

• Oncology
• Pharmacology

Background:

• Therapeutic strategies for metastatic breast cancer have advanced with novel agents like PARP inhibitors, CDK4/6 inhibitors, and immune checkpoint inhibitors.
• Antibody-drug conjugates (ADC) represent a newer therapeutic class, delivering cytotoxic agents directly to tumor cells, enhancing efficacy and minimizing systemic exposure.
• Sacituzumab govitecan and trastuzumab deruxtecan are two approved ADCs for HER2-negative metastatic breast cancer, though associated with significant adverse events.

Purpose of the Study:

• To provide a practical review of sacituzumab govitecan and trastuzumab deruxtecan for HER2-negative metastatic breast cancer.
• To discuss their mechanism of action, formulation, dosage, and integration into treatment regimens.
• To summarize key findings from Phase III clinical trials, with a focus on toxicity management.

Main Methods:

• Review of existing literature and clinical trial data.
• Analysis of mechanism of action, pharmacokinetics, and pharmacodynamics of the two ADCs.
• Synthesis of data regarding efficacy and safety profiles from Phase III trials.

Main Results:

• Sacituzumab govitecan and trastuzumab deruxtecan have demonstrated significant efficacy in HER2-negative metastatic breast cancer.
• Both ADCs are associated with substantial grade 3/4 adverse events in over 40% of patients.
• Clinical trial data highlight specific toxicity profiles requiring careful management.

Conclusions:

• ADCs have become important treatment options for HER2-negative metastatic breast cancer.
• Understanding the specific characteristics and toxicity profiles of sacituzumab govitecan and trastuzumab deruxtecan is crucial for optimal patient care.
• Further research and clinical practice guidelines are needed to refine the management of ADC-related toxicities.